BIRENDRA KUMAR SAH

Dr. BIRENDRA KUMAR SAH

Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
BIRENDRA KUMAR SAHBIRENDRA KUMAR SAH
BIRENDRA KUMAR SAH
BZBenyan Zhang
Benyan Zhang
HZHuan Zhang
Huan Zhang
JLJian Li
Jian Li
FYFei Yuan
Fei Yuan
ZZZhenggang Zhu
Zhenggang Zhu
Neoadjuvant chemotherapy with docetaxel, oxaliplatin, fluorouracil, and leucovorin (FLOT regimen) has shown promising results in terms of pathological response and survival rate in patients with locally advanced resectable gastric cancer (LAGC). However, tegafur gimeracil oteracil potassium capsule (S-1) plus oxaliplatin (SOX regimen) is the preferred chemotherapy regimen in Eastern countries. Here, we conduct an open label, two-arm, phase II randomized interventional clinical trial (Dragon III; ClinicalTrials.gov: NCT03636893) to evaluate the safety and efficacy of both regimens. Patients with LAGC are randomly assigned to receive either 4 cycles of the neoadjuvant FLOT regimen (40 patients) or 3 cycles of the SOX regimen (34 patients) before gastrectomy. The primary endpoint is the comparison of complete (TRG1a) or subtotal (TRG1b) tumor regression grading in the primary tumor. There are no significant differences in adverse effects or postoperative morbidity and mortality between the two groups. No significant differences in the proportion of tumor regression grading between the FLOT group and the SOX group are found. Complete or subtotal TRG is 20.0% in the FLOT group versus 32.4% in the SOX group. Therefore, our study does not find statistically significant differences between neoadjuvant FLOT and SOX regimens for the primary outcomes reported here in locally advanced gastric cancer.

9 December 2009 in BMC Cancer
Verified
Journal Article
Open access
PDF file
BIRENDRA KUMAR SAHBIRENDRA KUMAR SAH
BIRENDRA KUMAR SAH
MCMing-Min Chen
Ming-Min Chen
MYMin Yan
Min Yan
ZZZheng-Gang Zhu
Zheng-Gang Zhu
Background: The selection of an anastomosis method after a distal gastrectomy is a highly debatable topic; however, the available documentation lacks the necessary research based on a comparison of early postoperative complications. This study was conducted to investigate the difference of early postoperative complications between Billroth I and Billroth II types of anastomosis for distal gastrectomies.Methods: A total of 809 patients who underwent distal gastrectomies for gastric cancer during four years were included in the study. The only study endpoint was analysis of in-patients' postoperative complications. The risk adjusted complication rate was compared by POSSUM (Physiological and operative severity score for enumeration of morbidity and mortality) and the severity of complications was compared by Rui Jin Hospital classification of complication.Results: Complication rate of Billroth II type of anastomosis was almost double of that in Billroth I (P = 0.000). Similarly, the risk adjusted complication rate was also higher in Billroth II group. More severe complications were observed and the postoperative duration was significantly longer in Billroth II type (P = 0.000). Overall expenditure was significantly higher in Billroth II type (P = 0.000).Conclusion: Billroth II method of anastomosis was associated with higher rate of early postoperative complications. Therefore, we conclude that the Billroth I method should be the first choice after a distal gastrectomy as long as the anatomic and oncological environment of an individual patient allows us to perform it. However more prospective studies should be designed to compare the overall surgical outcomes of both anastomosis methods.

4 February 2022 in Future Oncology
Verified
Journal Article
Open access
SLSheng Lu
Sheng Lu
ZYZhong-Yin Yang
Zhong-Yin Yang
CYChao Yan
Chao Yan
WLWen-Tao Liu
Wen-Tao Liu
ZNZhen-Tian Ni
Zhen-Tian Ni
ZZZheng-Gang Zhu
Zheng-Gang Zhu
Although recent advances in systemic chemotherapy have improved the clinical outcomes of gastric cancer patients with peritoneal metastasis, the peritoneum still represents a common site of treatme... Plain language summary Recent advances in technology have improved the outcomes of stomach cancer patients. However, there are still many patients who die of cancer that has spread from another par...

5 October 2025 in eClinicalMedicine
Verified
Journal Article
Open access
BIRENDRA KUMAR SAHBIRENDRA KUMAR SAH
BIRENDRA KUMAR SAH
ZYZhenjia Yu
Zhenjia Yu
BZBenyan Zhang
Benyan Zhang
FYFei Yuan
Fei Yuan
HZHuan Zhang
Huan Zhang
ZZZhenggang Zhu
Zhenggang Zhu
Both FLOT (5-Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel) and SOX (S-1 plus Oxaliplatin) neoadjuvant regimens are widely used for locally advanced gastric cancer; however, direct head-to-head survival data to guide optimal treatment selection are lacking. This study aimed to compare long-term survival outcomes between neoadjuvant FLOT and SOX regimens in patients with locally advanced gastric cancer. This study reports the prespecified secondary outcomes of the DRAGON III trial, an open-label, randomised, exploratory phase 2 trial conducted at a single hospital (Ruijin Hospital) in China. Eligible participants were adults aged 18-80 years with histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction, clinical stage cT3-4b, cN1-3, cM0 disease, adequate organ function, and ECOG performance status ≤2. Participants were randomly assigned 1:1 using computer-generated simple randomisation without stratification to receive either neoadjuvant FLOT or SOX before D2 gastrectomy. The FLOT regimen consisted of four cycles of 5-Fluorouracil 2600 mg/m2, Leucovorin 200 mg/m2, Oxaliplatin 85 mg/m2, and Docetaxel 50 mg/m2, intravenous every 2 weeks. The SOX regimen consisted of three cycles of oxaliplatin 130 mg/m2 intravenous on day 1 and oral Tegafur/Gimeracil/Oteracil (S-1) 80 mg/m2 twice daily on days 1-14, repeated every 3 weeks. Neither patients nor investigators were blinded due to different administration protocols. The secondary endpoints were overall survival (defined as time from randomisation to death from any cause) and disease-free survival (defined as time from randomisation to first occurrence of local recurrence, regional recurrence, distant metastases, or death from any cause) with 5-year follow-up. Survival differences were assessed using log-rank test and Cox proportional hazards regression. All analyses followed intention-to-treat principles including all 74 randomised patients regardless of treatment completion. The trial is registered with ClinicalTrials.gov, NCT03636893. Between Aug 22, 2018, and Nov 14, 2019, 74 patients were randomised (40 FLOT, 34 SOX). In the FLOT group, 31/40 (77.5%) completed chemotherapy and surgery, with 9 patients not proceeding to surgery (1 withdrew consent, 4 refused surgery, 3 required early surgery due to bleeding, 1 serious adverse event). In the SOX group, 24/34 (70.6%) completed treatment, with 10 patients not proceeding to surgery (2 withdrew consent, 3 refused surgery, 1 died from treatment-related toxicity, 3 protocol violations, 1 adverse event). All survival analyses included the full intention-to-treat population of 74 patients. With median follow-up of 65.7 months, both regimens demonstrated comparable long-term survival outcomes. Median overall survival was 61.5 months (95% CI: not reached) for FLOT versus 67.8 months (95% CI: 25.7-109.9) for SOX, with no significant difference (HR 1.101, 95% CI: 0.595-2.036, p = 0.76). Disease-free survival was similarly comparable (median 23.0 versus 25.5 months, HR 1.060, 95% CI: 0.597-1.884, p = 0.84). Grade 3-4 haematological toxicity occurred in 9/40 (22.5%) FLOT patients versus 5/34 (14.7%) SOX patients. One treatment-related death occurred in the SOX group (2.9%) due to grade IV haematological toxicity followed by multiple organ failure. The findings of our exploratory phase 2 study suggest equivalent long-term survival between FLOT and SOX regimens, with both achieving favourable 5-year survival outcomes. However, these results should be interpreted cautiously given several important limitations. As an exploratory study without formal power calculations for survival endpoints, conducted at a single centre with a relatively small sample size, these findings require validation in adequately powered phase 3 trials before definitive conclusions can be drawn. The single-centre design and exclusively Asian population may limit generalizability to other settings and ethnic groups. Additionally, the study was not designed to formally test equivalence between regimens. Within these limitations, the results suggest that treatment selection may reasonably prioritise patient factors, institutional experience, and practical considerations. None.

18 January 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
BIRENDRA KUMAR SAHBIRENDRA KUMAR SAH
BIRENDRA KUMAR SAH
WXWei Xu
Wei Xu
BZBenyan Zhang
Benyan Zhang
HZHuan Zhang
Huan Zhang
FYFei Yuan
Fei Yuan
ZZZhenggang Zhu
Zhenggang Zhu
Background: Neoadjuvant fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) has shown significant benefits for gastric cancer patients. However, it has not been well accepted in Asian countries. We conducted a prospective study on the safety and feasibility of the FLOT regimen in Chinese patients. Methods: Patients with adenocarcinoma of the stomach or esophagogastric junction received four cycles of neoadjuvant chemotherapy (NAC) and four cycles of adjuvant chemotherapy (AC) with the FLOT regimen. The completion status of chemotherapy, adverse events, postoperative morbidities, and pathological tumor regression were analyzed. The 2-year overall survival (OS) and relapse-free survival are presented. Results: Altogether, 10 patients were enrolled, and all patients completed four cycles of neoadjuvant chemotherapy. There were no severe hematological adverse events (grade 3 or above), except for a case of grade 3 anemia. All 10 patients underwent radical gastrectomy. Nine patients had R0 resection, and three patients had complete or subtotal pathological tumor regression. Nine patients completed four cycles of adjuvant chemotherapy, but only one patient completed the full dose of adjuvant chemotherapy. The dose of adjuvant chemotherapy was reduced by 25% or less in the other patients. The median follow-up time was 23.13 months, eight patients achieved the overall survival endpoint, and seven patients had relapse-free survival for this period. Two patients died of disease progression. Conclusions: Our study demonstrates that the neoadjuvant FLOT regimen is safe and effective for Chinese patients. Dose adjustment is necessary for adjuvant chemotherapy. The pathological regression and survival rates need reevaluation in a larger cohort. The trial is registered with ClinicalTrials.gov (number NCT03646591).

9 January 2020 in BMC Surgery
Verified
Journal Article
Open access
PDF file
BIRENDRA KUMAR SAHBIRENDRA KUMAR SAH
BIRENDRA KUMAR SAH
JLJ. Li
J. Li
CYChao Yan
Chao Yan
CLChen Li
Chen Li
MYM. Yan
M. Yan
ZZZhenggang Zhu
Zhenggang Zhu
Background: An appropriate method of anastomosis is crucial for gastric cancer patients who require gastrojejunal anastomosis. Surgeons have proposed different types of modified gastrojejunostomies in the last two decades. We focused on two types of standard anastomosis, i.e., Uncut Roux-Y and Roux-Y gastrojejunostomies, and compared the differences in immediate postoperative complications between the two types. Methods: This is a retrospective study on 236 gastric cancer patients who underwent curative distal gastrectomy with gastrojejunal Roux-Y or Uncut Roux-Y anastomosis for six consecutive years. Immediate postoperative complications were compared between the two groups. The authors discussed the causes of the significant complications and their management. Results: There was no difference in demographics between the two groups (92 Roux-y Versus 144 Uncut Roux-y). The overall complication rate was 20.8% with 1.4% anastomotic leakage in the Uncut Roux-Y group versus 33.7% with 7.6% anastomotic failures in the Roux-Y group (p < 0.05). More abdominal infections occurred in the Roux-Y anastomosis group compared with the Uncut Roux-Y anastomosis group (p < 0.05). Duration of postoperative stay was significantly longer in patients with Roux-y anastomosis group (p < 0.05). Conclusions: Considering the surgical simplicity and postoperative complications, the Uncut Roux-Y is a better choice for anastomosis in patients with gastric cancer undergoing gastrojejunostomy. A well-designed large cohort in a multi-centre randomized controlled trial is necessary to support these findings and compare other aspects.